Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with lipoprotein subclasses

Metabolism: Clinical and Experimental

Volumn 53, Issue 10, 2004, Pages 1296-1304

  Klein, Richard L ^a,b,c   McHenry, M Brent ^b   Lok, Kerry H ^d   Hunter, Steven J ^a   Le, Ngoc Anh ^e   Jenkins, Alicia J ^a,f,g   Zheng, Deyi ^b   Semler, Andrea J ^a   Brown, W Virgil ^e   Lyons, Timothy J ^g   Garvey, W Timothy ^d,h,i  

^a Division of Endocrinology   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

ⁱ NDIC/DCCT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

3' UNTRANSLATED REGIONS; ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; DIABETES MELLITUS, TYPE 1; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARTICLE SIZE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TRIGLYCERIDES;

EID: 4544352163     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.05.004     Document Type: Article

References (57)

1. Schonfeld G., George P.K., Miller J., et al. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28:1979;1001-1010
2. Talmud P.J., Humphries S.E. Apolipoprotein C-III gene variation and dyslipidemia. Curr Opin Lipidol. 8:1997;154-158
3. Aalto-Setälä K., Kontula K., Sane T., et al. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis. 66:1987;145-152
4. Stocks J., Paul H., Galton D.J. Haplotypes identified by DNA restriction-fragment-length polymorphisms in A-I/C-III/A-IV gene region and hypertriglyceridemia. Am J Hum Genet. 41:1987;106-118
5. Ordovas J.M., Schaefer E.J., Salem D., et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med. 314:1986;671-677
6. Wile D.B., Barbir M., Gallagher J., et al. Apolipoprotein A-I gene polymorphisms Frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration. Atherosclerosis. 78:1989;9-18
7. Ordovas J.M., Civeira F., Genest J. Jr, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 87:1991;75-86
8. Lamarche B., Moojani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 94:1996;273-278
9. Dammerman M., Sandkuijl L.A., Halaas J.L., et al. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA. 90:1993;4562-4566
10. Li W.W., Dammerman M.M., Smith J.D., et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 96:1995;2601-2605
11. Aalto-Setala K., Fisher E.A., Chen X., et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 90:1992;1889-1900
12. Ebara T., Ramakrishnan R., Steiner G., et al. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E null mice Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 99:1997;2672-2681
13. Chen M., Breslow J.L., Li W., et al. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice Correlation with changes in plasma triglyceride levels. J Lipid Res. 35:1994;1918-1924
14. Hegele R.A., Connelly P.W., Hanley A.J., et al. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol. 17:1997;2753-2758
15. Shoulders C.C., Grantham T.T., North J.D., et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus Lack of association with the variant insulin response element in Italian school children. Hum Genet. 98:1996;557-566
16. Surguchov A.P., Page G.P., Smith L., et al. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 16:1996;941-947
17. Groenendijk M., Cantor R.M., Bloom N.H.H.C., et al. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. J Lipid Res. 40:1999;1036-1044
18. Dallongeville J., Meirhaeghe A., Cottel D., et al. Gender associated association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Arteriosclerosis. 150:2000;149-157
19. Hoffer M.J., Sijbrands E.J., De Man F.H., et al. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest. 28:1998;807-812
20. Wijsman E.M., Brunzell J.D., Jarvik G.P., et al. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol. 18:1998;215-226
21. Jong M.C., Hofker M.H., Havekes L.M. Role of apoCs in lipoprotein metabolism Functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol. 19:1999;472-484
22. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 12:2001;297-304
23. Renard E., Dupuy A.M., Monnier L., et al. DNA restriction polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster A genetic determinant of atherosclerosis in type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med. 8:1991;354-360
24. Rigoli L., Raimondo G., Di Benedetto A., et al. Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Acta Diabetol. 32:1995;251-256
25. Trembath R.C., Thomas D.J., Hendra T.J., et al. Deoxyribonucleic acid polymorphism of the apoprotein AI-CIII-AIV gene cluster and coronary heart disease in non-insulin-dependent diabetes. Br Med J Clin Res Ed. 294:1987;1577-1578
26. Jowett N.I., Rees A., Williams L.G., et al. Insulin and apolipoprotein A-I/C-III gene polymorphisms relating to hypertriglyceridaemia and diabetes mellitus. Diabetologia. 27:1984;180-183
27. Tas S., Abdella N.A. Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus Relation to apolipoprotein CIII gene polymorphism. Lancet. 343:1994;1194-1195
28. Peacock R.E., Temple A., Gudnason V., et al. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland Interaction between genotype, gender, and smoking status. Genet Epidemiol. 14:1997;265-282
29. EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 22:1999;977-986
30. Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type 1 diabetic patients and nondiabetic subjects. Diabetes. 44:1995;1093-1098
31. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem. 37:1991;377-386
32. Otvos J.D., Jeyarajah E.J., Bennett D.W., et al. Development of a proton NMR spectroscopic method for determining plasma lipoprotein concentrations and subspecies distribution from a single, rapid measurement. Clin Chem. 38:1992;1632-1638
33. Otvos J., Jeyarajah E., Bennett D. A spectroscopic approach to lipoprotein subclass analysis. J Clin Ligand Assay. 19:1996;184-189
34. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 48:2002;171-180
35. Freedman D.S., Otvos J.D., Jeyarajah E.J., et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 18:1998;1046-1053
36. Le N.-A., Innis-Whitehouse W., Li X., et al. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia Effect of triglyceride reduction with atorvastatin. Metabolism. 49:2000;167-177
37. DCCT Research Group. DCCT Manual of Operations. 1993;National Technical Information Service, Springfield, VA. 93-183382
38. Hedrick P.W. Gametic disequilibrium measures Proceed with caution. Genetics. 117:1987;331-341
39. Terwilliger J.D., Ott J. Handbook of Genetic Linkage. 1994;Johns Hopkins Press, Baltimore, MD
40. Blankenhorn D.H., Alaupovic P., Wichham E., et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts Lipid and nonlipid factors. Circulation. 81:1990;470-476
41. Jenkins A.J., Lyons T.J., Zheng D., et al. Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort. Associations with gender and glycemia. Diabetes Care. 26:2003;810-818
42. Hodis H.N., Mack W.J., Azen S.P., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49
43. Luc C., Fievet C., Arveiler D., et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction The ECTIM study. J Lipid Res. 37:1996;508-517
44. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:2000;1886-1892
45. Koren E., Corder C., Mueller G., et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 122:1996;105-115
46. Gervaise N., Garrigue M.A., Lasfargues G., et al. Triglycerides, apo C3, and LpB C3 and cardiovascular risk in type II diabetes. Diabetologia. 43:2000;703-708
47. Humphries S.E., Berglund L., Isasi C.R., et al. Loci for CETP, LPL, LIPC, and APOC3 affect plasma lipoprotein size and sub-population distribution in Hispanic and non-Hispanic white subjects The Columbia University BioMarkers Study. Nutr Metab Cardiovasc Dis. 12:2002;163-172
48. Russo G.T., Meigs J.B., Cupples L.A., et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk The Framingham Offspring Study. Atherosclerosis. 158:2001;173-181
49. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 81:1998;13B-17B
50. Kuller L., Rrnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 22:2002;1175-1180
51. Blake G.J., Otvos J.D., Rifai N., et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106:2002;1930-1937
52. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the Healthy Women Study. Am J Cardiol. 90:(suppl):2002;71i-76i
53. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am J Cardiol. 90:2002;89-94
54. Lee S.-J., Campos H., Moye L.A., et al. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 23:2003;853-858
55. Batal R., Tremblay M., Barrett P.H., et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 41:2000;706-718
56. Windler E., Havel R.J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 26:1985;556-565
57. Kowal R.C., Harz J., Weisgraber K.H., et al. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 265:1990;10771-10779